Navigation Links
FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Date:9/23/2008

ndolol, we are taking a major step forward in our quest to bring the benefits of personalized medicine to cardiovascular disease," said Richard B. Brewer, president and chief executive officer of ARCA biopharma. "We look forward to working with the FDA to make bucindolol available to physicians and patients. We are also working with our partner, LabCorp of America, to develop and introduce a companion genetic test."

In the genetic sub-study of the BEST trial, researchers categorized patients into three groups based on receptor genotype: very favorable, favorable and unfavorable. Patients with the very favorable genotype experienced significant improvements in clinical endpoints compared to placebo, including reductions in all cause mortality, all cause mortality or transplant, cardiovascular mortality, heart failure hospitalization, and cardiovascular hospitalization. While the most robust clinical effects occurred in the very favorable genotype group, patients with the favorable genotype also benefited from treatment with bucindolol. Bucindolol also demonstrated clinically significant improvements in ischemic endpoints including reducing the risk of myocardial infarction. Patients with the unfavorable genotype, approximately 10 percent of the study population, did not respond to bucindolol therapy.

About Beta Blockers

The use of beta blockers is the standard of care in patients with heart failure and left ventricular dysfunction, according to clinical practice guidelines of the Heart Failure Society of America (HFSA), the American Heart Association, and the American College of Cardiology. HFSA guidelines state: "Beta-blocker therapy remains a major advance in the treatment of patients with LV systolic dysfunction. Along with ACE inhibitors, this class of drug is now established as routine therapy in patients with LV systolic dysfunction."

About Heart Failure

Heart failure is a chronic and progressive condition in which the heart c
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. FDA Accepts Ranexa(R) sNDA and NDA for Filing
4. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
5. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
6. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
7. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
8. FDA Accepts Immucors Response to Warning Letter
9. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
10. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... Calif., March 12 ,Exelixis, Inc. (Nasdaq: EXEL ) ... executive officer of Exelixis, will present at the,Cowen and ... / 1:00 p.m.,PT on Monday, March 17, 2008. Dr. ... corporate strategy., The presentation will be webcast and ...
... DIEGO, March 12 Biomatrica, the leader in ... a reagent that enhances PCR and RT-PCR performance ... amplification of genomic,DNA or RNA templates., PCRboost ... that are,traditionally difficult to amplify and present in ...
... 12 Oncolys BioPharma,Inc. (Tokyo, Japan) and Tacere ... they have entered into a strategic alliance and,license ... interference (RNAi)-based Hepatitis C virus (HCV) compound, TT-033,code-named ... the,strategic alliance entered into by Tacere and Oncolys ...
Cached Biology Technology:Biomatrica's PCRboost(TM) Enables 5-Fold Improvement in Amplification of Difficult Samples 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small Cap ... report showed that planet-wide, transactions at merchants on the leading ... total number of credit, debit, and prepaid cards reached 6.54 ... victims of fraudulent card usage in 2012, and credit and ...
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Infinisource's NXG series sets new time clock standard 2
... Ridge Associated Universities (ORAU), a consortium of 98 Ph.D.-granting ... sciences in the University of Delaware,s College of Earth, ... Junior Faculty Enhancement Award. The competitive award, which ... from the faculty member,s university, is intended to enrich ...
... the National Oceanography Centre (NOC) joins forces with the ... Porcupine Abyssal Plain sustained observatory (PAP-SO), the longest multidisciplinary ... advance scientific understanding of the ocean and improve climate ... North Atlantic off the Irish continental margin, where the ...
... PITTSBURGH, May 25 A two-year, $12 million contract ... Transition (OTT) will jumpstart human trials of three innovative ... with healthy, functional tissues, announced officials of the University ... today at the Institute,s Second Annual Open Session, Soldiers ...
Cached Biology News:University of Delaware professor wins Powe Award from Oak Ridge Associated Universities 2University of Delaware professor wins Powe Award from Oak Ridge Associated Universities 3Met Office and NOC enhance ocean observatory 2Pitt gets $12 million DoD contract for regenerative medicine treatment trials 2
Request Info...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
...
Biology Products: